GoodRx Holdings, Inc. (NASDAQ:GDRX) Q2 2023 Earnings Conference Call August 9, 2023 8:00 AM ET

Company Participants

Scott Wagner - Interim CEO

Karsten Voermann - CFO

Raj Beri - COO

Whitney Notaro - VP, IR

Conference Call Participants

Charles Rhyee - TD Cowen

Jonathan Yong - Credit Suisse

Jailendra Singh - Truist Securities

George Hill - Deutsche Bank

Stan Berenshteyn - Wells Fargo Securities, LLC

Sandy Draper - Guggenheim Securities, LLC

Daniel Grosslight - Citigroup

Jian Li - Evercore ISI

McCoy Madson - Morgan Stanley

Robert Simmons - D.A. Davidson & Co.

Thomas Kelliher - RBC Capital Markets

Eric Sheridan - Goldman Sachs

Operator

Good day, and thank you for standing by. Welcome to the GoodRx Second Quarter 2023 Earnings Conference Call and Webcast. [Operator instructions]. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Whitney Notaro, Vice President of Investor Relations. Please go ahead.

Whitney Notaro

Thank you, operator. Good morning, everyone, and welcome to GoodRx's earnings conference call for the second quarter 2023. Joining me today are Scott Wagner, our Interim Chief Executive Officer, and Karsten Voermann, our Chief Financial Officer. Raj Beri, our Chief Operating Officer, will also be joining for the Q&A portion of today’s call.

Before we begin, I'd like to remind everyone that this call will contain forward-looking statements. All statements made on the call that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding management's plans, strategies, goals and objectives, our market opportunity, our anticipated financial performance, the ongoing impact of the former grocer issue on our business, underlying trends in our business, our potential for growth, collaborations and partnerships with third parties, anticipated impacts of the deprioritization of certain solutions under our Pharma Manufacturer Solutions offering, and our cost savings initiatives, our direct contracting approach with retailers, realizability of our deferred tax assets, and the expected impact from the macroeconomic environment on our business. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors. These factors may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

Factors discussed in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our quarterly report on Form 10-Q for the quarter ended March 31, 2023, and our other filings with the Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made on this call. Any such forward-looking statements represent management's estimates as of the date of this call, and we disclaim any obligation to update these statements, even if subsequent events cause our views to change. In addition, we may also reference non-GAAP metrics, which are reconciled to the nearest GAAP metrics in the company's earnings press release, which can be found on the Overview page of our Investor Relations website at investors.GoodRx.com. I'd also like to remind everyone that a replay of this call will become available there shortly as well.